 |
|
|
|
Cancer
Immunity, Vol. 4, p. 14 (25 November 2004)
Submitted: 5 August 2004. Accepted: 11 October 2004.
Communicated by: H zur Hausen
Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells
Yvette Schwitalle, Michael Linnebacher, Eva Ripberger,
Johannes Gebert, and Magnus von Knebel Doeberitz
Institute of Molecular Pathology, University of Heidelberg, D-69120 Heidelberg, Germany
Keywords:
microsatellites, frameshift
mutation, peptide, caspase-5, T lymphocyte epitope
|
|
|
|
|
|
Abstract
About 15% of all human colorectal, gastric, and endometrial tumors, and the majority of tumors in patients suffering from hereditary nonpolyposis colorectal cancer syndrome, are caused by loss of DNA mismatch repair functions. In the affected cancer cells, this results in insertion or deletion mutations at short, repetitive DNA sequences referred to as microsatellites. Such mutations in coding microsatellites (cMS) cause translational frameshifts that may destroy gene function. These frameshift mutations could also cause the translation of immunogenic neopeptides at the carboxy terminus. Several such mutations have been identified recently. However, since none of the frameshift-induced neopeptides identified so far is generated in all cancer cells with microsatellite instability (MSI), we aim to define a broad but comprehensive set of frameshift peptides (FSPs) that might be combined in a multivalent vaccine for MSI+ cancers. Here, we characterize the immunogenic properties of five additional HLA-A0201-restricted frameshift-induced neopeptides derived from mutations in three cMS-containing genes (Caspase-5, TAF-1b, and HT001) that are frequently hit in MSI+ cancer cells. One Caspase-5-derived FSP, 67-FLIIWQNTM (FSP26), was identified as a novel HLA-A0201-restricted CTL epitope. FSP26-specific CTLs efficiently lysed colon carcinoma cells expressing HLA-A0201 and the underlying (-1) mutation. This mutation in an A(10) cMS is observed in up to 66% of MSI+ colorectal cancers. Thus, this newly identified CTL epitope may be another essential component of a multivalent vaccine against cancers with MSI.
|
